CLINUVEL is established to address unmet medical needs, with a particular focus on patients with brain and skin disorders. One of the specialties of the firm is photomedicine, serving populations at highest risk from UV and light exposure.
The Company’s key operating activities encompass:
- the distribution of its novel pharmaceutical photoprotective SCENESSE® (afamelanotide 16mg) for patients with erythropoietic protoporphyria (EPP);
- the development of pharmaceutical products, including SCENESSE®, PRÉNUMBRA® and NEURACTHEL®, and the conduct of clinical programs for patients who require medical solutions; and
- the commercialisation of a range of PhotoCosmetic products to provide healthcare solutions for people at highest risk of UV and light, DNA-damage and requiring MSH-response as melanogenic (bronzing) protectant.
The review of operations details the key activities and developments in each of these areas over the year ending 30 June 2023 (FY2023).